United States: Unreliable Expert Causation Evidence Ends Birth Defect Case

Last Updated: February 21 2017
Article by Eric Alexander

We have posted several times in the last few years (like here, here, here, and here) about cases alleging birth defects from maternal SSRI use during pregnancy. Perhaps because of the inherent sympathy for the plaintiff (offspring), it seems that plaintiffs in birth defect cases get extra chances to prove that have enough science to support their claims. Science in this area is undoubtedly complicated. For one thing, while ontogeny does not always recapitulate phylogeny, fetal development of placental mammals (of which humans are a relatively recently evolved species) varies, so extrapolation from animal studies on teratogenic effects is even harder than with studies of direct effects on animals. For another, ethical considerations generally preclude prospective clinical trials designed to study teratogenic effects. FDA's treatment of drug labeling on the risks of teratogenic effects has reflected some of this dynamic.

Litigations pursuing birth defect claims seem to follow their own dynamic. Despite the oft-cited caution from Rosen v. Ciba-Geigy Corp., 78 F.3d 316, 319 (7th Cir. 1996), that "the courtroom is not the place for scientific guesswork, even of the inspired sort. Law lags science; it does not lead it," it often seems like cases are pursued before there is science to support them, particularly if specificity of drug, dosage, and injury is going to be required. This may be due to the impact of statutes of limitations. It may also be because some courts are lenient on admissibility of causation evidence and there can be years from filing a case a case until Daubert (or equivalent) motions are decided. Another dynamic seems to be that the only proof as to whether the plaintiff's mother took the drug during the relevant time can be her word, unless the plaintiff's expert can argue that the birth defect can itself count as proof of exposure. We also sometimes see that general causation can be a harder concept for courts to understand than it should be.

Looking through our particular lens, we see all of this in K.E. v. Glaxosmithkline LLC, No. 3:14-cv-1294(VAB), 2017 U.S. Dist. LEXIS 13705 (D. Conn. Feb. 1, 2017), a case that came to the correct result—causation opinions excluded—but took an overly charitable route in arriving there. The case alleged that maternal use of the defendant's SSRI during the first trimester of her pregnancy with plaintiff in 2001 caused him to develop a bicuspid aortic valve and accompanying regurgitation. The plaintiff was diagnosed with a bicuspid aortic valve in September 2010 (after evaluation following his father's diagnosis with his own heart condition), by which time the drug's label had been revised to reflect the pregnancy category D—"adverse reaction data from investigational or marketing experience or studies [of the drug] in humans"—and the manufacturer had sent a dear healthcare provider letter describing the basis for the change. Id. at **16-18. The purported prescribing physician testified that he would not have prescribed the drug to a patient whom he suspected was pregnant or recommended it for a pregnant woman based on the label as it was in 2001. Id. at **16-17. We say "purported prescribing physician" because he denied prescribing the drug to plaintiff's mother until after the plaintiff was born, which is what his records and pharmacy records—but not plaintiff's mother's testimony—showed. Id. at **9-12. More on that later. After the bicuspid valve diagnosis, plaintiff's records suggested that his mother had used the drug during pregnancy and his mother—plaintiff was still a minor—thought that there was a relationship. This was reinforced by a lawyer advertisement on television trolling for plaintiffs and she contracted and signed up with a law firm to pursue a lawsuit over plaintiff's bicuspid aortic valve by September 2011. Id. at **18-19. Even though the statute of limitations in Connecticut for claims like this was two years, plaintiff waited until late July 2014—close to four years after the diagnosis—to sue. Within a year—pretty fast for such cases—the manufacturer moved to exclude plaintiff's sole causation expert and for summary judgment on statute of limitations, lack of causation, and other problems with plaintiff's proof. The decision we are discussing followed more than eighteen months later.

We will save some suspense by noting that the claim was time-barred (as the parties seemed to agree that the mother's knowledge not the minor plaintiff's determined accrual) and that almost all the other claims would have failed anyway even if plaintiff had admissible evidence of medical causation. That negligence per se predicated on violating "federal regulations" and "negligent pharmacovigilance," again based on federal requirements rather than state law duties, were not tossed on their merits need not lead to a rant here. We also do not need to spend time on the analysis that plaintiff could not avoid summary judgment on any claim without a medical causation expert. Instead, we can focus on the Daubert challenge to plaintiff's expert, a pediatric cardiologist with research experience in congenital heart defects, who opined that maternal use of the drug was a "significant contributing factor" to the plaintiff's bicuspid valve.

The first challenge was to qualifications and, not surprisingly, it failed. It is hard to exclude professor from a top medical school on a subject that seems fairly relevant to the issues in the case. The court held that his expertise extended to "hypothetical ways that [the drug] might affect embryonic serotonin levels and cause heart defects" even though he had no specific research or writing experience with "serotonin's role in heart development." Id. at *29.

The second challenge was to the expert's general causation opinion. This is where we will take a moment to explain something that seems to be missing: a discussion of the expert's methodology for forming a general causation opinion. In other words, what did this expert think he needed to establish general causation between the drug and the type of injury and how did he go about analyzing the issue from available evidence? Daubert decisions, including ones cited in K.E., often look to the Bradford Hill criteria as an accepted framework for evaluating the issue of general causation. Like in K.E., the evaluation of epidemiological evidence and the evaluation of biological plausibility tend to take up most of the court's discussion and both are part of old Sir Austin's seminal work. The mistake that K.E. made—which did not change the outcome but prolonged the analysis—is that there is no role for biological plausibility unless there is a strong association consistently demonstrated in epidemiological studies. A patchwork causation case may be made through multiple experts—remember, the plaintiff in K.E. had only one—but there is no accepted methodology for evaluating causation, certainly for teratogenic effects, that would let general causation be established with biological plausibility and not epidemiology.

When the plaintiff's expert failed to offer a reliable opinion that the epidemiology supported general causation, that should have been it. Not just for his general causation opinion, but for the entire case because there is no such thing as an admissible specific causation opinion when general causation has not been established. His opinion on epidemiology failed for the same reason others have failed in SSRI birth defect cases, he did not look at all the relevant studies, specifically seven meta-analyses. Id. at **30-31. While the court did not think this was intentional cherry picking, it rendered his analysis incomplete and unreliable. Id. at **32-33. We cannot tell the strength of association in any of the studies he did consider, if it was statistically significant, or if it was consistent, but it looks like the studies lumped together various cardiac defect rather than bicuspid aortic valves—they are supposed to have three cusps—as they should have to support a general causation opinion, assuming other criteria were also met.

In addition to being moot given the ruling on the epidemiology piece of the expert's general causation opinion, the court's consideration of biological plausibility—the area where the expert's qualifications were also light—was pretty lenient. The expert could not "specify exactly how [the drug] or another SSRI would impact the prenatal environment in a human" or how much serotonin would produce any change relevant to bicuspid valves. Id. at *36. "Potential plaintiffs, however, would be overly burdened by a standard that would disallow any expert testimony on serotonin's effect on animals because the optimal range of serotonin in pregnant women is unknown." Id. Daubert imposed a gatekeeping role for a reason, knowing that plaintiffs have the burden of proof. The K.E. court's response that "the significant limitations of the studies on which [the expert] relies . . . would be best addressed with precautionary instructions to the jury and rigorous cross examination" is misguided when there is a clear analytical gap that should preclude admission. Id. at *37. The same goes for the court's claim that the jury could "form its own assessment of [the plaintiff's expert's] reliability" after hearing from the defense expert. Id. at *38. Assessing reliability is what the court has to do before it admits testimony, as we have said recently.

Based on no admissible opinion on epidemiology and an admissible—but admittedly shaky—opinion on biological plausibility, the court turned to the expert's specific causation opinion. As we said, the plaintiff's expert should not have gotten that far. But he did not last long because "the record contains very little evidence that [the plaintiff's mother] consumed [the drug] while she was pregnant and no evidence from which [the expert] can reasonable infer how much" she took. Id. at *40. There was also no evidence suggesting any use would have been during the time period when it was purportedly biologically plausible that there could have been an effect on aortic valve development. This was enough to preclude any specific causation opinion. The court patiently went through the plaintiff's arguments that the expert could still offer an admissible specific causation opinion, including the claim that a differential diagnosis does proof of exposure—he could not rule out alternative causes let alone reliably rule in exposure—but there was no rescuing such a speculative opinion. Here, the court noted that there was "too great an analytical gap" between studies suggesting an association—including the epidemiological studies he was already precluded from opining on—and a causation opinion in a case with no real evidence of relevant exposure. Id. at *53. It seems pretty clear that, even with a decade and a half lag from the plaintiff's birth until the court's decision, there was too great a gap to allow any reliable opinion of causation. So, while we may think it went on too long—like this post—the result seems correct.

This article is presented for informational purposes only and is not intended to constitute legal advice.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions